[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100363604":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":25,"responsibleParty":40,"collaborators":10,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":10,"eligibilityCriteria":47,"healthyVolunteers":44,"sex":48,"minAge":49,"maxAge":10,"enrollmentInfo":50,"targetDuration":53,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":10,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},{"fullName":5,"class":6},"Kyowa Kirin Co., Ltd.","INDUSTRY",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Transplant Arm",null,"Patients with CTCL or ATLL who received mogamulizumab within one year prior or up to 18 months after alloHCT",{"label":13,"type":10,"description":14,"interventionNames":10},"Control Arm","Patients who have undergone alloHCT without exposure to mogamulizumab pre- or post-alloHCT",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Linda J Burns, MD","CONTACT","414-805-0714","lburns@mcw.edu",{"name":22,"role":18,"phone":23,"phoneExt":10,"email":24},"Jatin Jadwani, BDS, MSc Clinical Research","+49 15114861167","jatin.jadwani@kyowakirin.com",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":10},"CIBMTR","RECRUITING","Milwaukee","Wisconsin","53226","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-87.90647,43.0389,{"lat":38,"lon":37},{"type":41,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100363604","post-authorization-safety-study-of-allogeneic-hematopoietic-stem-cell-transplantation-in-patients-treated-with-mogamulizumab-100363604",false,"NCT04014374","Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab","Inclusion Criteria:\n\n* Patients registered to the Center for International Blood and Marrow Transplant Research (CIBMTR)\n* Adults ≥18 years of age with either CTCL or ATLL;\n* AlloHCT performed from January 2012 onward.\n\nExclusion Criteria:\n\n• Patients without consent for research.","ALL","18 Years",{"count":51,"type":52},150,"ESTIMATED","2 Years","OBSERVATIONAL","This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted beginning January 1, 2012 until accrual is complete.",[57,58,59],"Leukemia\u002FLymphoma","Cutaneous T Cell Lymphoma","ATLL","2024-07-23",{"date":62,"type":63},"2024-07-24","ACTUAL",{"date":65,"type":63},"2019-09-10",{"date":67,"type":52},"2030-02",{"name":69,"class":6},"Kyowa Kirin, Inc.",1]